Cargando…
Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
Lupus Nephritis (LN) is the most common manifestation of severe organ damage for systemic lupus erythematosus (SLE) patients. Severe active LN could result in acute kidney injury (AKI), which could even require Kidney Replacement Therapy (KRT). Therefore, there needs to be a more proactive and safe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511409/ https://www.ncbi.nlm.nih.gov/pubmed/36172377 http://dx.doi.org/10.3389/fimmu.2022.977377 |
_version_ | 1784797635588128768 |
---|---|
author | Zhang, Chengning Zeng, Ming Ge, Yifei Liu, Kang Xing, Changying Mao, Huijuan |
author_facet | Zhang, Chengning Zeng, Ming Ge, Yifei Liu, Kang Xing, Changying Mao, Huijuan |
author_sort | Zhang, Chengning |
collection | PubMed |
description | Lupus Nephritis (LN) is the most common manifestation of severe organ damage for systemic lupus erythematosus (SLE) patients. Severe active LN could result in acute kidney injury (AKI), which could even require Kidney Replacement Therapy (KRT). Therefore, there needs to be a more proactive and safe induction therapy to quickly and effectively control renal immune inflammation, maintain kidney function or reverse kidney damage. While multiple clinical studies have proven the efficacy and safety of Belimumab in treating SLE and LN, these studies have not included cases of severe LN requiring KRT. We observed the effectiveness and safety of Belimumab in treating four severe active LN patients undergoing KRT. With Belimumab administered at a dosage of 10mg/kg, all four patients were able to discontinue KRT with no adverse events (AEs) to date ultimately. These cases provided an excellent basis for the application of Belimumab combined with standard therapy to LN patients with a medium to severe kidney injury. |
format | Online Article Text |
id | pubmed-9511409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95114092022-09-27 Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review Zhang, Chengning Zeng, Ming Ge, Yifei Liu, Kang Xing, Changying Mao, Huijuan Front Immunol Immunology Lupus Nephritis (LN) is the most common manifestation of severe organ damage for systemic lupus erythematosus (SLE) patients. Severe active LN could result in acute kidney injury (AKI), which could even require Kidney Replacement Therapy (KRT). Therefore, there needs to be a more proactive and safe induction therapy to quickly and effectively control renal immune inflammation, maintain kidney function or reverse kidney damage. While multiple clinical studies have proven the efficacy and safety of Belimumab in treating SLE and LN, these studies have not included cases of severe LN requiring KRT. We observed the effectiveness and safety of Belimumab in treating four severe active LN patients undergoing KRT. With Belimumab administered at a dosage of 10mg/kg, all four patients were able to discontinue KRT with no adverse events (AEs) to date ultimately. These cases provided an excellent basis for the application of Belimumab combined with standard therapy to LN patients with a medium to severe kidney injury. Frontiers Media S.A. 2022-09-12 /pmc/articles/PMC9511409/ /pubmed/36172377 http://dx.doi.org/10.3389/fimmu.2022.977377 Text en Copyright © 2022 Zhang, Zeng, Ge, Liu, Xing and Mao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhang, Chengning Zeng, Ming Ge, Yifei Liu, Kang Xing, Changying Mao, Huijuan Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review |
title | Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review |
title_full | Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review |
title_fullStr | Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review |
title_full_unstemmed | Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review |
title_short | Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review |
title_sort | effectiveness and safety of belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: a case report and literature review |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511409/ https://www.ncbi.nlm.nih.gov/pubmed/36172377 http://dx.doi.org/10.3389/fimmu.2022.977377 |
work_keys_str_mv | AT zhangchengning effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview AT zengming effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview AT geyifei effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview AT liukang effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview AT xingchangying effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview AT maohuijuan effectivenessandsafetyofbelimumabcombinedwithstandardtherapyinsevereactivelupusnephritisrequiringkidneyreplacementtherapyacasereportandliteraturereview |